E-Cigarette Effects ON Markers of Cardiovascular AND Pulmonary Disease Risk

电子烟对心血管和肺部疾病风险标志物的影响

基本信息

  • 批准号:
    10245273
  • 负责人:
  • 金额:
    $ 45.64万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-09-14 至 2023-08-31
  • 项目状态:
    已结题

项目摘要

Project Summary/Abstract E-cigarette use is increasing rapidly in the United States, especially amongst youth, underscoring the vital need to improve understanding of its health risks. Relevant data could inform policy, guide public health and clinical intervention efforts, and inform individuals who might use or who are using this product. In this proposal, we describe research that will significantly enhance our understanding of the health effects of E-cig use by relating the acute and long-term use of E-cigs and conventional cigarettes (“products”) to well- validated cardiovascular and pulmonary disease biomarkers. We will enroll 4 different “use-groups” of participants (n=440): exclusive E-cig users (n=110), exclusive cigarette smokers (n=110), dual product users (who both smoke and vape: n=110), and never smokers (n=110). These groups reflect the primary decisions that individuals can make regarding their future tobacco use: to continue to smoke cigarettes, to switch to E- cigs, to use both cigarettes and E-cigs, or to not use products. It is essential that smokers and health care providers have accurate information on the health effect of these choices. Product use will be related to well-validated biomarkers that accurately and reproducibly reflect mechanisms, injury, and future risks related to cardiovascular or pulmonary disease. Biomarkers will be related to (1) acute product use in the laboratory (exposure challenges), (2) lifetime history of product use, and/or (3) real-time measures of product use in participants' daily lives. The primary cardiovascular biomarkers are brachial artery flow-mediated dilation (a measure of endothelial function) and carotid intima-media thickness, a measure of subclinical arterial injury and atherosclerosis. The primary pulmonary disease biomarkers will be measures of lung volumes and flow rates (predicted FEV1, FVC, FEV1/FVC) obtained by spirometry. We also will perform treadmill exercise stress testing (to assess aerobic fitness), electrocardiography (to measure heart rate and its variability) and measure blood pressure, lipids, HgbA1c, and inflammation/oxidation markers (leukocyte count, C-reactive protein, urinary F2 isoprostanes) and exhaled nitric oxide. We will show how product use-groups differ in response to (1) acute product use and (2) long-term use regarding cardiovascular and pulmonary biomarkers. We also will determine how history of product use is related to biomarker status. The proposed research will yield vital and comprehensive data regarding product use, subclinical arterial injury, atherosclerosis burden, arterial and pulmonary function, cardiac and aerobic fitness, cardiac autonomic dysregulation, systemic and pulmonary inflammation, and oxidative stress, as well as other key outcomes. These data will serve as a foundation for future longitudinal investigations of E-cig health effects and will inform public policy decisions, clinical interventions, and patient guidance regarding E-cigarettes.
项目总结/摘要 在美国,电子烟的使用正在迅速增加,特别是在年轻人中,这突显了电子烟的重要性。 我们需要提高对健康风险的认识。相关数据可以为政策提供信息,指导公共卫生, 临床干预工作,并告知可能使用或正在使用本产品的个人。 在这份提案中,我们描述的研究将大大提高我们对健康影响的理解 电子烟的使用,将电子烟和传统香烟(“产品”)的急性和长期使用与 验证心血管和肺部疾病的生物标志物。我们将招募4个不同的“使用组”, 受试者(n=440):电子烟专用者(n=110)、香烟专用者(n=110)、双产品使用者 (who吸烟和电子烟:n=110),从不吸烟者(n=110)。这些组反映了主要决策 个人可以对他们未来的烟草用途:继续吸烟,转向电子烟, 香烟,同时使用香烟和电子烟,或者不使用产品。至关重要的是,吸烟者和卫生保健 提供者对这些选择的健康影响有准确的信息。 产品使用将与经过充分验证的生物标志物相关,这些生物标志物准确且可重现地反映 机制、损伤和与心血管或肺部疾病相关的未来风险。生物标志物将与 (1)实验室中的急性产品使用(暴露挑战),(2)产品使用的终身史,和/或(3) 实时测量参与者日常生活中的产品使用情况。主要的心血管生物标志物是 肱动脉血流介导的扩张(内皮功能的测量)和颈动脉内膜中层厚度, 亚临床动脉损伤和动脉粥样硬化的测量。主要肺部疾病生物标志物将是 通过肺活量测定法获得的肺容量和流速(预测的FEV 1、FVC、FEV 1/FVC)的测量值。我们也 我将进行跑步机运动压力测试(评估有氧健身),心电图(测量心脏 心率及其变异性),并测量血压、血脂、HbA 1c和炎症/氧化标志物 (白细胞计数,C-反应蛋白,尿F2异前列腺素)和呼出的一氧化氮。我们将展示如何 产品使用组对(1)急性产品使用和(2)长期使用的心血管反应不同 和肺部生物标志物。我们还将确定产品使用史与生物标志物状态的关系。 拟议的研究将产生有关产品使用、亚临床动脉 损伤、动脉粥样硬化负荷、动脉和肺功能、心脏和有氧适应性、心脏自主神经 失调,全身和肺部炎症,氧化应激,以及其他关键结果。 这些数据将作为未来电子烟健康影响的纵向调查的基础,并将提供信息。 公共政策决策,临床干预和关于电子烟的患者指导。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Timothy B Baker其他文献

Timothy B Baker的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Timothy B Baker', 18)}}的其他基金

Optimized Chronic Care for Smokers: Developing and Implementing Integrated Clinical and Systems Interventions in Primary Care
优化吸烟者的长期护理:在初级护理中制定和实施综合临床和系统干预措施
  • 批准号:
    10415915
  • 财政年份:
    2014
  • 资助金额:
    $ 45.64万
  • 项目类别:
Testing Relapse Recovery Intervention Components
测试复发恢复干预成分
  • 批准号:
    8655747
  • 财政年份:
    2014
  • 资助金额:
    $ 45.64万
  • 项目类别:
Optimized Chronic Care for Smokers: Developing and Implementing Integrated Clinical and Systems Interventions in Primary Care
优化吸烟者的长期护理:在初级护理中制定和实施综合临床和系统干预措施
  • 批准号:
    10627882
  • 财政年份:
    2014
  • 资助金额:
    $ 45.64万
  • 项目类别:
Optimized Chronic Care for Smokers: Developing and Implementing Integrated Clinical and Systems Interventions in Primary Care
优化吸烟者的长期护理:在初级护理中制定和实施综合临床和系统干预措施
  • 批准号:
    10215407
  • 财政年份:
    2014
  • 资助金额:
    $ 45.64万
  • 项目类别:
Enhancing the Effectiveness of Varenicline Based Smoking Cessation Treatment
提高基于伐尼克兰的戒烟治疗的有效性
  • 批准号:
    9311480
  • 财政年份:
    2011
  • 资助金额:
    $ 45.64万
  • 项目类别:
Intervention Optimization Core
干预优化核心
  • 批准号:
    7612555
  • 财政年份:
    2009
  • 资助金额:
    $ 45.64万
  • 项目类别:
Identifying Optimal, Translatable Tobacco Cessation Interention Components
确定最佳的、可转化的戒烟干预成分
  • 批准号:
    7612559
  • 财政年份:
    2009
  • 资助金额:
    $ 45.64万
  • 项目类别:
Training in Translational Tobacco Science
转化烟草科学培训
  • 批准号:
    7918941
  • 财政年份:
    2008
  • 资助金额:
    $ 45.64万
  • 项目类别:
Training in Translational Tobacco Science
转化烟草科学培训
  • 批准号:
    7689810
  • 财政年份:
    2008
  • 资助金额:
    $ 45.64万
  • 项目类别:
Training in Translational Tobacco Science
转化烟草科学培训
  • 批准号:
    8324683
  • 财政年份:
    2008
  • 资助金额:
    $ 45.64万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 45.64万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 45.64万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 45.64万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 45.64万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 45.64万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 45.64万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 45.64万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 45.64万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 45.64万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 45.64万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了